These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 10451192)

  • 1. Anaphylaxis upon switching lipid-containing amphotericin B formulation.
    Cronin JE; Barron RL
    Clin Infect Dis; 1999 Jun; 28(6):1342. PubMed ID: 10451192
    [No Abstract]   [Full Text] [Related]  

  • 2. Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation.
    Mohr JF; Hall AC; Ericsson CD; Ostrosky-Zeichner L
    Pharmacotherapy; 2005 Mar; 25(3):426-8. PubMed ID: 15843289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the current and future status of conventional amphotericin B?
    Kleinberg M
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutritional impact of lipid-associated amphotericin B formulations.
    Sacks GS; Cleary JD
    Ann Pharmacother; 1997 Jan; 31(1):121-2. PubMed ID: 8997484
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia.
    Frothingham R
    Clin Infect Dis; 2002 Oct; 35(7):896-7; author reply 897-8. PubMed ID: 12228830
    [No Abstract]   [Full Text] [Related]  

  • 6. Compatibility of amphotericin B with drugs used to reduce adverse reactions.
    Gotz VP; Mar DD; Roche JJ
    Am J Hosp Pharm; 1981 Mar; 38(3):378-9. PubMed ID: 7223754
    [No Abstract]   [Full Text] [Related]  

  • 7. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections.
    Sachs-Barrable K; Lee SD; Wasan EK; Thornton SJ; Wasan KM
    Adv Drug Deliv Rev; 2008 Mar; 60(6):692-701. PubMed ID: 18053611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amphotericin B: is a lipid-formulation gold standard feasible?
    Spellberg B; Witt MD; Beck CK
    Clin Infect Dis; 2004 Jan; 38(2):304-5; author reply 306-7. PubMed ID: 14699470
    [No Abstract]   [Full Text] [Related]  

  • 9. Lipid formulations of amphotericins: are you a lumper or a splitter?
    Wingard JR
    Clin Infect Dis; 2002 Oct; 35(7):891-5. PubMed ID: 12228829
    [No Abstract]   [Full Text] [Related]  

  • 10. Lipid formulations of amphotericin B.
    Dix SP; Andriole VT
    Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B deoxycholate administered by continuous infusion: does the dosage make a difference?
    Hiemenz JW
    Clin Infect Dis; 2003 Apr; 36(8):952-3. PubMed ID: 12684905
    [No Abstract]   [Full Text] [Related]  

  • 12. [Amphotericin B and lipids: a new formulation].
    Ordóñez J; García A; Ferrándiz R
    Nutr Hosp; 1994; 9(2):114-5. PubMed ID: 8031949
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of a new formulation of amphotericin B in a murine model of disseminated infection by Candida glabrata.
    Mariné M; Espada R; Torrado J; Pastor FJ; Guarro J
    J Antimicrob Chemother; 2008 Apr; 61(4):880-3. PubMed ID: 18256113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of amphotericin B lipid complex.
    Franklin IM; Mehta J; Root T
    J Antimicrob Chemother; 1997 Feb; 39(2):288-90. PubMed ID: 9069558
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute amphotericin B overdose.
    Burke D; Lal R; Finkel KW; Samuels J; Foringer JR
    Ann Pharmacother; 2006 Dec; 40(12):2254-9. PubMed ID: 17090724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of successful treatment of cutaneous Acanthamoeba infection in a lung transplant recipient.
    Walia R; Montoya JG; Visvesvera GS; Booton GC; Doyle RL
    Transpl Infect Dis; 2007 Mar; 9(1):51-4. PubMed ID: 17313473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABLE: a new and improved amphotericin B for visceral leishmaniasis?
    Berman J
    Am J Trop Med Hyg; 2009 May; 80(5):689-90. PubMed ID: 19407106
    [No Abstract]   [Full Text] [Related]  

  • 18. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis.
    Syriopoulou V; Daikos GL; Theodoridou M; Pavlopoulou I; Manolaki AG; Sereti E; Karamboula A; Papathanasiou D; Krikos X; Saroglou G
    Clin Infect Dis; 2003 Mar; 36(5):560-6. PubMed ID: 12594635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B for the treatment of severe fungal infection.
    Michaud D
    Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acrocyanosis developed with amphotericin B deoxycholate but not with amphotericin B lipid complex.
    Ozaras R; Yemisen M; Mete B; Mert A; Ozturk R; Tabak F
    Mycoses; 2007 May; 50(3):242. PubMed ID: 17472626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.